Barry D. Quart
2018
In 2018, Barry D. Quart earned a total compensation of $6M as President and Chief Executive Officer at Heron Therapeutics, a 41% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $552,973 |
|---|---|
| Option Awards | $4,815,660 |
| Salary | $614,414 |
| Other | $8,250 |
| Total | $5,991,297 |
Quart received $4.8M in option awards, accounting for 80% of the total pay in 2018.
Quart also received $553K in non-equity incentive plan, $614.4K in salary and $8.3K in other compensation.
Rankings
In 2018, Barry D. Quart's compensation ranked 1,572nd out of 14,244 executives tracked by ExecPay. In other words, Quart earned more than 89.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,572 out of 14,244 | 89th |
Division Manufacturing | 552 out of 5,765 | 90th |
Major group Chemicals And Allied Products | 171 out of 2,128 | 92nd |
Industry group Drugs | 134 out of 1,817 | 93rd |
Industry Pharmaceutical Preparations | 98 out of 1,391 | 93rd |
Source: SEC filing on April 23, 2020.
Quart's colleagues
We found three more compensation records of executives who worked with Barry D. Quart at Heron Therapeutics in 2018.
News
Heron Therapeutics CEO Craig Collard receives $11M in 2023
April 29, 2024
Heron Therapeutics Executive Vice President, Drug Development Kimberly Manhard's 2022 pay falls 22% to $1.4M
May 1, 2023
Heron Therapeutics CEO Barry Quart's 2021 pay rises 2% to $5.4M
April 25, 2022
Heron Therapeutics CEO Barry Quart's 2020 pay slips 9% to $5.3M
April 22, 2021
Heron Therapeutics CEO Barry Quart's 2019 pay slips 2% to $5.9M
April 23, 2020